Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Rita Nanda"'
Autor:
Zahi Mitri, Kimberly B. Koenig, Catherine Van Poznak, Gabriel N. Hortobagyi, Stacy Moulder-Thompson, Caimiao Wei, Abenaa M. Brewster, Ilona Hood, Kimberly L. Blackwell, Colleen M. Costelloe, Mothaffar F. Rimawi, Rita Nanda, Nuhad K. Ibrahim
Publikováno v:
Clinical Cancer Research. 22:5706-5712
Purpose: Osteoclast-mediated bone resorption through src kinase releases growth factors, sustaining bone metastases. This trial determined the recommended phase II dose (RP2D) and clinical efficacy of the src kinase inhibitor dasatinib combined with
Autor:
Funda Meric-Bernstam, Rita Nanda, Andres Forero, Kandace P. McGuire, Clifford A. Hudis, Mehra Golshan, S Hwang, Janet K. Horton, Michael Alvarado, Terry Hyslop, Timothy M. Zagar, Tina J. Hieken
Publikováno v:
Cancer Research. 76:S3-06
Background:Neoadjuvant chemotherapy (NCT) is used frequently to downstage locally advanced tumors and facilitate breast conservation. However, we have previously reported that achievement of radiographic complete response (rCR) or pathologic complete
Autor:
Antonio C. Wolff, Nan Lin, Julie R. Nangia, William J. Irvin, Rita Nanda, Dafydd G. Thomas, Catherine Van Poznak, Minetta C. Liu, Kimberly Aung, Kelley M. Kidwell, Christos Vaklavas, Tiffany A. Traina, Martha E. Brown, Anna Maria Storniolo, Daniel F. Hayes, Costanza Paoletti, Andres Forero-Torres, Vandana G. Abramson, Maria C. Muñiz, Yufeng Li
Publikováno v:
Clinical Cancer Research. 21:2771-2779
Purpose: Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). We tested whether EpCAM-based capture system (CellSearch) is effective in patients with triple-negative (TN) MBC, and whether CTC apoptosis and clustering enhanc
Autor:
Eric P. Winer, Amy C. Peterson, Javier Cortes, Vandana G. Abramson, Tiffany A. Traina, Maureen E. Trudeau, Joyce O'Shaughnessy, Denise A. Yardley, Peter Schmid, Martha Elizabeth Blaney, Lee S. Schwartzberg, Joyce Steinberg, Catherine M. Kelly, Rita Nanda, Iulia Cristina Tudor, Ahmad Awada, Clifford A. Hudis
Publikováno v:
Cancer Research. 75:P5-19
Background AR expression has been observed in 10-30% of patients with TNBC. AR+ TNBC cell lines demonstrated enhanced growth in response to androgen stimulation that is inhibited by enzalutamide (ENZA), a potent oral inhibitor of AR signaling. AR+ TN
Autor:
Kristi McIntyre, Jonathan R Young, Leona B Downey, William Kubasek, John W. Smith, Ian E. Krop, Joyce O'Shaughnessy, Kerry E Horgan, Cynthia Osborne, Gavin MacBeath, Rita Nanda, Manuel R Modiano, Frankie A. Holmes, Michael A. Danso, Manish Gupta, Mansoor N. Saleh
Publikováno v:
Cancer Research. 75:P3-11
Background: MM-121 is a fully human monoclonal antibody that targets ErbB3 and blocks heregulin (HRG), the principal ligand for ErbB3, from binding. HRG-driven ErbB3 signaling has been widely implicated in the development of resistance to conventiona
Autor:
E. Claire Dees, Edward Gonzalez, Christine K. Gause, Lajos Pusztai, Kumudu Pathiraja, Raanan Berger, Ravit Geva, Johnathan D Cheng, Robert Iannone, Laurence Buisseret, Jennifer Houp, Vassiliki Karantza, Kenneth Emancipator, Shilpa Gupta, Marisa Dolled-Filhart, Rita Nanda, Laura Q.M. Chow
Publikováno v:
Cancer Research. 75:S1-09
Introduction: The PD-1 receptor-ligand pathway can be used by tumors to evade immune surveillance, thereby allowing neoplastic growth. Pembrolizumab is a highly selective, humanized IgG4/kappa isotype mAb designed to block PD-1 interaction with its l
Autor:
Rita Nanda, Dafydd G. Thomas, William J. Irvin, Julie R. Nangia, Martha E. Brown, MC Liu, Andres Forero, Maria C. Muñiz, TA Traina, Kimberly Aung, Yufeng Li, Vandana G. Abramson, Kelley M. Kidwell, Nu Lin, Costanza Paoletti, Daniel F. Hayes, Antonio C. Wolff, Anna Maria Storniolo, C. Van Poznak, Christos Vaklavas
Publikováno v:
Cancer Research. 73:P1-04
Background: Circulating Tumor cells (CTCs) are prognostic at baseline and first follow-up in patients with metastatic breast cancer (MBC). Using the most commonly used assay (CellSearch®), we have previously reported the ability to detect apoptotic
Autor:
Gini F. Fleming, Tessa Cigler, G. Somlo, A. A. Garcia, Paul Frankel, Joanne E. Mortimer, MP Goetz, Arti Hurria, T Luu, Timothy J. Moynihan, David R. Gandara, Rita Nanda, Jeffrey N. Weitzel, Alice P. Chen, Cynthia X. Ma, Linda T. Vahdat, Banu Arun, Joseph A. Sparano, Harold A. Harvey, H Chew
Publikováno v:
Cancer Research. 73:P2-16
Background: The potential for exploiting BRCA deficiencies with DNA repair inhibitors has both pre-clinical and clinical support. ABT-888 (veliparib), a DNA repair inhibitor initially thought to target Poly(ADP-Ribose) Polymerases (PARP), has demonst
Autor:
Amy Voci, Ingrid M. Meszoely, C. Van Poznak, Gildy Babiera, ES Hwang, Michael Alvarado, Mehra Golshan, L Bijelic, Lisa K. Jacobs, Judy C. Boughey, Helen Krontiras, Anna Maria Storniolo, Kandace P. McGuire, Rita Nanda, Claudine Isaacs, EP Winer, Larry Norton, Jaclyn P. Lyman, Antonio C. Wolff, Mithat Gonen, Ta King, Monica Morrow, MC Liu, HS Rugo, Clifford A. Hudis, Camilla Boafo
Publikováno v:
Cancer Research. 73:P2-18
Background: Retrospective studies suggest that primary breast surgery is associated with improved overall survival (OS) in Stage IV breast cancer. TBCRC 013 is a multi-center prospective registry study evaluating the role of surgery for the primary t
Autor:
Clifford A. Hudis, Funda Meric-Bernstam, Mehra Golshan, Janet K. Horton, Rita Nanda, Ingrid M. Meszoely, Alan B. Cantor, Los Santos Jf De, S Hwang, Andres Forero, Kandace P. McGuire, Keith D. Amos
Publikováno v:
Cancer Research. 71:P2-15
Background: Neoadjuvant chemotherapy is increasingly used to downstage locally advanced tumors, test new regimens, and improve chances of breast conservation. In parallel, use of breast MRI for surgical planning and as a potential response biomarker